MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. Show more
Location: 11711 North Meridian Street, Carmel, IN, 46032, United States | Website: https://mbxbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
388.1M
52 Wk Range
$4.81 - $27.50
Previous Close
$11.61
Open
$11.65
Volume
425,670
Day Range
$11.47 - $12.42
Enterprise Value
140.7M
Cash
240.8M
Avg Qtr Burn
-16.66M
Insider Ownership
3.12%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MBX 1416 Details Post-Bariatric Hypoglycemia | Phase 2 Initiation | |
MBX 4291 Details Obesity | Phase 1 Initiation |